TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03392428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA617
Description: Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment.
Study: NCT03497039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Diethylamine (DDEA) gel
Description: Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
Study: NCT04140786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate, Injectable
Description: 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate, Injectable
Description: 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
Study: NCT01818843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: Inhaled Carbon Monoxide in newborn
Study: NCT05859646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic use
Description: Probiotics were used for 3 months and all participated patients were followed for 6 months.
Study: NCT00858351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thermal Biofeedback Assisted Relaxation
Description: 6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion with therapist
Description: 6 sessions, 25 minutes each, discussing topics with a therapist.
Study: NCT00778167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01446887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylactic anticoagulation
Description: prophylactic anticoagulation by rivaroxaban
Study: NCT01541488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: drinking solution / tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1021958
Description: SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
Study: NCT02151656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F17464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00087984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-002
Description: Dendritic Cell Immunotherapy
Study: NCT02709720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 1 and 2 day 1, 80 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 3 and 4 day 1, 80 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concomitant therapy during cycles 3 and 4. Total dose: 66Gy
Study: NCT00972517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Three intramuscular injections
Study: NCT04105959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution
Study: NCT01152801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Study: NCT02446821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeraCept
Description: IUD placement of VeraCept
Study: NCT02199093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation of apraxia
Description: The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional health educative protocol
Description: The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
Study: NCT01102491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
Study: NCT05532228

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: adenotonsillectomy by cold dissection

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: adenotonsillectomy by cold dissection

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: adenotonsillectomy by cold dissection

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: adenotonsillectomy by cold dissection
Study: NCT05762042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary supplement
Description: Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement
Description: Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally.
Study: NCT01010451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial pulpotomy
Description: Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide pulpectomy
Description: Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
Study: NCT02953561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01791621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elimination/Challenge Diet
Description: An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team.
Study: NCT00731861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus PTK787
Description: Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.
Study: NCT02013349

Intervention type: DEVICE
Group type: OTHER
Intervention: coronary intervention
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast
Description: Cardiac MRI
Study: NCT01148693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Distilled water
Study: NCT03485222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 6 months
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI without contrast
Description: Cardiac MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Hematocrit, Creatinine, Troponin, BNP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Hematocrit, Creatinine, Troponin, BNP
Study: NCT01179269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Paclitaxel
Description: Pazopanib daily and weekly paclitaxel IV
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Hematocrit, Creatinine, Troponin, BNP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Holter Monitor
Study: NCT02298309

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test-and-Treat TB
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Holter Monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Holter Monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test
Study: NCT04310319

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodiumchloride
Description: Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodiumchloride
Description: Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Protein
Description: Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Genetic Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Genetic Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Genetic Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeat MRI scan
Description: Repeat MRI scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeat MRI scan
Description: Repeat MRI scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeat MRI scan
Description: Repeat MRI scan
Study: NCT01914627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone
Description: The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
Study: NCT03485222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo equivalent for 6 months
Study: NCT01914627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic Acid
Description: The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
Study: NCT04310319

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Protein
Description: Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (salt)
Description: Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (salt)
Description: Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (protein)
Description: Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (protein)
Description: Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
Study: NCT02006108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-GE Healthcare 3 Tesla magnet
Description: All patients will undergo
Study: NCT03015155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of Cold Saline into Local Infarction Myocardium.
Description: Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
Study: NCT03948893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
Study: NCT00550186

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers Lactate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HaemoHES 6%
Study: NCT01412125

Intervention type: OTHER
Intervention: Huntington patient evaluation
Description: Neurological, neuropsychological, neuroimaging evaluation and biological sample

Intervention type: OTHER
Intervention: Healthy subject evaluation
Description: Neurological, neuropsychological, neuroimaging evaluation and biological sample
Study: NCT04556526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ad26.ZEBOV
Description: Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MVA-BN-Filo
Description: Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
Study: NCT02906410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item-Level Calorie information
Description: Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item-Level Calorie information
Description: Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item-Level Calorie information
Description: Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item-Level Calorie information
Description: Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal-Level Calorie information
Description: Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal-Level Calorie information
Description: Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen.
Study: NCT04152954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of cervical medial branches
Description: Radiofrequency ablation of cervical medial branches

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of cervical medial branches
Description: Radiofrequency ablation of cervical medial branches
Study: NCT01492426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film-coated tablet, oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Film-coated tablet, oral, 750 mg, 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 μg, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 μg, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day